US Stock MarketDetailed Quotes
INZY Inozyme Pharma
- 2.720
- +0.070+2.64%
Close Nov 27 16:00 ET
- 2.730
- +0.010+0.37%
Post 19:36 ET
174.73MMarket Cap-1754P/E (TTM)
2.740High2.580Low1.11MVolume2.690Open2.650Pre Close2.96MTurnover3.04%Turnover RatioLossP/E (Static)64.24MShares7.79552wk High2.11P/B99.45MFloat Cap2.56052wk Low--Dividend TTM36.56MShs Float31.650Historical High--Div YieldTTM6.04%Amplitude0.991Historical Low2.664Avg Price1Lot Size
About Inozyme Pharma Company
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.
Company Profile
SymbolINZY
Company NameInozyme Pharma
Listing DateJul 24, 2020
Issue Price16.00
Founded2015
CEODr. Douglas A. Treco, PhD
MarketNASDAQ
Employees59
Fiscal Year Ends12-31
Address321 Summer Street,Suite 400
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02210
Phone1-857-330-4340
Websitehttp://www.inozyme.com
Company Executives
- Name
- Position
- Salary
- Dr. Douglas A. Treco, PhD
- Chairman of the Board and Chief Executive Officer
- 5.30M
- Sanjay Subramanian
- Chief Financial Officer, Principal Accounting Officer and Corporate Secretary
- 1.03M
- Matthew Winton
- Chief Operations Officer
- 1.55M
- Axel Bolte
- Director
- 1.80M
- Erik Harris
- Director
- --
- Reinaldo M. Diaz
- Lead Independent Director
- 130.27K
- Dr. Sarah Bhagat, PhD
- Independent Director
- 114.65K
- Lynne Sullivan
- Independent Director
- 122.15K
- Dr. Martin William Edwards, M.D.
- Independent Director
- 129.65K
- Edward T. Mathers
- Independent Director
- 116.15K
- Dr. Robert Hopfner, M.B.A.,PhD,R.Ph.
- Independent Director
- 112.15K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data